NasdaqGM - Nasdaq Real Time Price USD

iTeos Therapeutics, Inc. (ITOS)

7.81

-0.16

(-2.01%)

At close: May 16 at 4:00:01 PM EDT

8.12

+0.31

+(3.97%)

After hours: May 16 at 7:41:39 PM EDT

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

Zacks yesterday

ITOS
-2.01%

NVS
GSK and iTeos drop anti-TIGIT drug following trial failure

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024.

Clinical Trials Arena 2 days ago

ITOS
-2.01%
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK) assessed the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small cell lung cancer (NSCLC). The GALAXIES Lung-201 data demonstrated clinically meaningful improvements in the trial’s objective response rate (ORR) endpoint. Also Read: Brit

Benzinga 3 days ago

ITOS
-2.01%

GSK
GSK, iTeos Therapeutics End Belrestotug Development Program

GSK (GSK) and iTeos Therapeutics (ITOS) said Tuesday they are ending the development program for bel

PREMIUM
MT Newswires 3 days ago

ITOS
-2.01%
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the disco

GlobeNewswire 3 days ago

ITOS
-2.01%
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 14 days ago

ITOS
-2.01%
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and developm

GlobeNewswire 18 days ago

ITOS
-2.01%
Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

Key Insights Given the large stake in the stock by institutions, iTeos Therapeutics' stock price might be vulnerable to...

Simply Wall St. 27 days ago

ITOS
-2.01%
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual

GlobeNewswire last month

ITOS
-2.01%
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

The consensus price target hints at a 212.5% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 2 months ago

ITOS
-2.01%
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

iTeos Therapeutics ( NASDAQ:ITOS ) Full Year 2024 Results Key Financial Results Revenue: US$35.0m (up 178% from FY...

Simply Wall St. 2 months ago

ITOS
-2.01%
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 WATERTOWN

GlobeNewswire 2 months ago

ITOS
-2.01%
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

ITOS
-2.01%
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

ITOS
-2.01%
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase 1 monotherapy and PD-1 combination data anticipated in 2H25 - EOS-215, a potential best-in-class anti-TREM2 monoclonal antibody, IND submission anticipated in 1Q25 - Cash balance and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 WAT

GlobeNewswire 4 months ago

ITOS
-2.01%
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30

GlobeNewswire 4 months ago

ITOS
-2.01%
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended b

TipRanks 4 months ago

ITOS
-2.01%
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

iTeos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments.

Clinical Trials Arena 4 months ago

ITOS
-2.01%
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS- Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed- Inupadenant deprioritized to

GlobeNewswire 5 months ago

ITOS
-2.01%
iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: 7Th Annual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Tuesday, December 3, 2024Time: 9:35

GlobeNewswire 5 months ago

ITOS
-2.01%

Performance Overview

Return	ITOS	S&P 500 (^GSPC)
YTD	+1.69%	+1.30%
1-Year	-56.37%	+12.48%
3-Year	-57.32%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

iTeos Therapeutics, Inc. (ITOS)

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

GSK and iTeos drop anti-TIGIT drug following trial failure

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

GSK, iTeos Therapeutics End Belrestotug Development Program

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos to Participate in Upcoming Investor Conferences

Performance Overview